PLATFORM AND TECHNOLOGY

Core Technology

The company has over ten R&D projects in the pipeline, covering autologous CAR-T products for common hematologic malignancies and solid tumors, allogeneic universal CAR products, point-of-care T-Oly manufacturing process products, and In Vivo CAR products. Through continuous technological iterations, we have significantly shortened production cycles, substantially reduced manufacturing costs, and enhanced patient accessibility.
Autologous Products
PrecisionCAR
PRIMCAR®
RESCAR®
HyeCAR®
PhiCAR®
Humanized structure, high effectiveness, High safety and long-lasting efficacy, Targeting the tumor immune microenvironment, Make breakthroughs in the tumor physical microenvironment, Recognition of multiple antigens, prevention of relapse.

· PrecisionCAR: Advanced humanized design, optimizationof full vector and full linker , ImmEVL immunogenicity evaluation system suitable for Chinese population, to create more effective CAR-T products.

· PRIMCAR®: Faster and more effective CAR-T preparation scheme; lower dose, less side-effect, and more durable human therapeutic effects; all efforts are made only to ensure that patients are more accessible.

· RESCAR®: Solutions of tumor immunosuppressive microenvironment , say "no" to the suppression signal , and stimulate potential in a repressed environment.

· HyeCAR®: Solutions of addressing CAR-T tumor arrival and survival in the tumor microenvironment.

· PhiCAR®: Multi-target CAR technology, which can simultaneously independently or cooperatively target different targets or multiple epitopes of the same target.

Universal Products Convenient and fast, high uniformity
C-1-144
C-2-90
U-1-2
C-35-X
The leading LstCAR universal CAR-T solution; unique CAR-NK vector design, efficient NK transduction and in vitro expansion, to create a convenient, fast, and high uniformity of universal CAR cell products.
Point-of-Care Manufacturing Technology Ultra-Fast, High-Efficiency Manufacturing
Leveraging three decades of CGT expertise and proprietary viral vector technologies, we have developed a one-step, ultra-short (T-Oly) process, enabling future outpatient treatment.
In Vivo Products One Shot, In Vivo Generation
We are developing a revolutionary "In Vivo CAR-T" platform. Using our proprietary targeted lentiviral and LNP technologies, it replaces the complex, lengthy traditional manufacturing process.